Cross Country Healthcare, Inc.

Cross Country Healthcare, Inc. (CCRN) Market Cap

Cross Country Healthcare, Inc. has a market capitalization of $428.1M.

Price: $13.25

▲ 0.00 (0.00%)

Market Cap: 428.06M

NASDAQ ¡ time unavailable

CEO: Kevin Cronin Clark

Sector: Industrials

Industry: Staffing & Employment Services

IPO Date: 2001-10-25

Website: https://www.crosscountry.com

Cross Country Healthcare, Inc. (CCRN) - Company Information

Market Cap: 428.06M|Sector: Industrials

Company Profile

Cross Country Healthcare, Inc. is a U.S.-based provider specializing in talent management and consultative advisory services for healthcare organizations. The company operates through two main divisions: Nurse and Allied Staffing, and Physician Staffing. The Nurse and Allied Staffing segment offers a broad range of recruitment and personnel solutions under the Cross Country brand. This includes both temporary and direct-hire placements for travel nurses, local nurses, and various allied health professionals. It sources registered nurses, licensed practical nurses, certified nurse assistants, practitioners, and pharmacists for per diem or short-term engagements, as well as clinical and non-clinical specialists for longer contract durations. Additionally, this segment delivers comprehensive workforce solutions, including Managed Service Programs (MSP), Recruitment Process Outsourcing (RPO), and consulting, alongside retained and contingent search services for healthcare professionals. Its diverse clientele spans public and private hospitals (both acute and non-acute care), government facilities, national and local healthcare plans, managed care providers, public and charter schools, outpatient clinics, ambulatory care centers, and physician practice groups. The Physician Staffing segment, operating as Cross Country Locums, focuses on supplying independent contractor physicians across numerous specialties, certified registered nurse anesthetists (CRNAs), nurse practitioners, and physician assistants. These professionals are deployed on temporary assignments to various healthcare environments, such as acute and non-acute care facilities, medical group practices, government establishments, and managed care organizations. Cross Country Healthcare, Inc. was established in 1986 and is headquartered in Boca Raton, Florida.

Analyst Sentiment

35%
Underperform

From 9 Active Polls

1Y Forecast: $12.50

▼ -5.7% Potential Upside

Consensus Target Metrics

Low Bound

$11

Median

$13

High Bound

$14

Average

$13

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$12.50
▼ -5.66% Upside
Low Target
$11.00
-17% Risk
Median Target
$12.50
-6% Mid
High Target
$14.00
6% Max
Consensus
Hold
2 / 14 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)428296262462424481587444465
Enterprise Value ($M)325192155365346403509384400
Price to Earnings Ratio (P/E)-4.34-16.79-0.79-23.67-16.31-186.13-37.8343.41-7.28
Price/Earnings-to-Growth Ratio (PEG)—-9.25———————
Price to Sales Ratio (P/S)0.431.231.111.851.551.641.891.411.37
Price to Book Ratio (P/B)1.330.950.811.131.031.151.401.041.06
Price to Free Cash Flow Ratio (P/FCF)10.8189.4016.2525.77188.45126.6627.0669.925.84
Enterprise Value to Sales (EV/Sales)—0.800.661.461.261.371.641.221.18
Enterprise Value to EBITDA (EV/EBITDA)-4.74383.02-2.33-367.49-320.2991.33127.9545.53-48.15
Debt to Equity Ratio1.510.010.010.010.010.010.010.010.01

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 CROSS COUNTRY HEALTHCARE INC (CCRN) — Investment Overview

🧩 Business Model Overview

CROSS COUNTRY HEALTHCARE INC operates a healthcare workforce services platform that matches clinicians to healthcare providers across a mix of staffing and workforce solutions. The value chain typically includes (1) recruiting and maintaining a pipeline of qualified healthcare professionals, (2) credentialing and compliance (licensure, onboarding, and background checks), (3) matching clinicians to facility demand, and (4) managing billing, payroll support, and service delivery under contractual terms.

The core “how it works” dynamic is a two-sided operational network: provider demand generates placement volume, which reinforces recruiting effectiveness and clinician retention. Over time, deeper provider relationships can translate into repeat business and more stable contract structures (including managed services and vendor-like arrangements), which can improve visibility into utilization and gross margin.

💰 Revenue Streams & Monetisation Model

Revenue is primarily driven by clinician placements billed to healthcare facilities. Monetisation generally follows a staffing model where the gross margin depends on the spread between what the facility pays and the fully-loaded cost of clinician compensation and related operating expenses (e.g., payroll-related costs and direct operating overhead).

  • Transactional staffing revenue: Billable hours and assignment-based placements.
  • Workforce solutions / managed services (where applicable): Contract structures that can reduce placement friction and support more recurring demand patterns.

Key margin drivers include the productivity of recruiting (ability to supply the right clinicians quickly), the efficiency of credentialing and onboarding, contract pricing discipline, and cost control on clinician compensation and related operational expenses. Scale and operational discipline matter because staffing economics are sensitive to utilization rates and the speed of matching supply to demand.

🧠 Competitive Advantages & Market Positioning

CCRN’s competitive position is strongest where it can embed into healthcare provider workforce planning rather than operating purely as a low-touch staffing marketplace. The practical “moat” is an integrated ecosystem that combines clinician supply, compliance/credentialing capability, and provider contracting know-how.

  • High switching costs (institutional/process friction): Providers face administrative and operational overhead when changing staffing partners—credentialing workflows, recruiter learning curves, and continuity for specialty staffing. This effect is strongest in managed service arrangements and high-acuity specialty demand where reliability is valued.
  • Integrated ecosystem (two-sided network effects): A larger and more qualified clinician pipeline improves fill rates, which can support provider satisfaction and repeat business; higher provider demand, in turn, supports recruiting and retention efforts.
  • Regulatory/compliance barriers to entry: Licensing, credentialing, and onboarding requirements create ongoing operational complexity. Competitors must maintain compliant processes and systems at scale to compete effectively for provider contracts.
  • Cost advantage through scale: Centralized back-office functions, standardized onboarding, and higher throughput recruiting can lower unit costs per placement versus smaller, less diversified staffing firms.

Competitive benchmarking:

  • AMN Healthcare (AMN): Similar healthcare staffing and workforce solutions focus, competing strongly on national supply and provider relationships. AMN typically emphasizes scaled workforce offerings across specialties.
  • Aya Healthcare (AYA): Direct staffing and digital-enabled recruiting presence with emphasis on clinician supply and assignment fulfillment.
  • Randstad (Randstad Healthcare platforms/affiliates): Broad staffing capability with healthcare as one vertical among several, competing through breadth and enterprise relationships.

CCRN’s positioning is characterized by a specialization and service-driven approach designed to deepen provider relationships through operational reliability and compliance execution, whereas many competitors compete either more heavily on clinician acquisition efficiency, broad staffing scale, or platform-driven demand capture. The differentiator is less about proprietary “technology IP” and more about the execution quality across recruiting, credentialing, and contract service delivery.

🚀 Multi-Year Growth Drivers

  • Structural healthcare labor needs: Demographic aging and increasing care intensity support long-run demand for staffing capacity and flexibility across healthcare settings.
  • Provider reliance on workforce flexibility: Hospitals and health systems increasingly manage labor utilization through contingent staffing and managed workforce models to balance cost and capacity demands.
  • Nursing/specialty shortages: Persistent shortages in certain clinician categories support ongoing demand for recruiters with strong credentialing throughput and assignment fulfillment performance.
  • Managed services penetration: Vendor-like arrangements and workforce solutions can increase the durability of revenue streams versus purely assignment-based models by aligning staffing with provider planning cycles.
  • Contracting sophistication and specialty depth: Expanding into specialties and facility types where operational reliability and compliance matter can widen addressable market even if appointment cycles fluctuate.

⚠ Risk Factors to Monitor

  • Regulatory and classification risk: Changes in rules affecting clinician classification, contracting practices, or compliance requirements can impact economics and operational processes.
  • Labor supply and wage pressure: Staffing gross margin is sensitive to competition for clinician supply and compensation costs, particularly during tight labor markets.
  • Client contracting dynamics: Providers can renegotiate pricing, alter vendor panels, or shift to in-house capacity or alternative staffing models, pressuring spreads.
  • Demand volatility: Utilization and assignment volumes can fluctuate with healthcare procedure volumes, seasonality, and policy-driven reimbursement changes.
  • Technology-enabled disintermediation: Digital staffing marketplaces can compress fees or reduce the value of traditional recruiting execution if they scale clinician supply and fill rates effectively.
  • Concentration and credit exposure: A significant portion of revenue can be exposed to a limited set of provider clients; billing disputes or delayed payments can affect working capital.

📊 Valuation & Market View

Healthcare staffing firms are typically valued through earnings-based and cash-flow metrics because revenue and margins can be sensitive to utilization and labor costs. Market participants often focus on:

  • Adjusted EBITDA / operating margin profile: Reflects staffing spread durability and operating leverage from recruiting and back-office scale.
  • Quality of revenue: The mix between assignment-based staffing and more managed, contract-structured revenue can influence stability.
  • Working capital dynamics: Billing cadence and payroll-related timing can affect free cash flow conversion.
  • Fill-rate and margin resilience: Indicators of ability to secure demand while maintaining pricing discipline versus labor cost inflation.

In practice, valuation tends to move with perceptions of (1) margin sustainability, (2) competitive positioning in clinician supply and provider contracts, and (3) the credibility of operating discipline through staffing cycle variability.

🔍 Investment Takeaway

CCRN’s long-term investment case rests on an operational moat built from compliance-heavy workforce infrastructure, clinician supply management, and provider relationship depth that can create meaningful switching friction. While the staffing industry remains cyclical and wage-sensitive, the strongest relative positioning comes from an integrated ecosystem that supports reliable fills, efficient credentialing, and durable contract relationships—elements that are difficult to replicate quickly at scale.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for CCRN.

marketbeat.com•2026-07-17

Cross Country Healthcare Clears Key Hurdle as Stockholders Approve Merger

Cross Country Healthcare NASDAQ: CCRN stockholders approved the company's proposed merger agreement at a virtual special meeting held July 16, according to remarks delivered during the meeting by Kevin Clark, the company's co-founder, CEO and chairman of the board.

businesswire.com•2026-07-15

CCRN Stock Alert: Halper Sadeh LLC is Investigating Whether Cross Country Healthcare, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Cross Country Healthcare, Inc. (NASDAQ: CCRN) to Knox Lane for $13.25 per share in cash.Halper Sadeh encourages Cross Country shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected] investigation concerns whether Cross Country and its board of direct.

globenewswire.com•2026-07-15

$HAREHOLDER ALERT: The M&A Class Action Firm Encourages $hareholders to Act Before the Vote—Cross Country Healthcare, Inc. (NASDAQ: CCRN)

NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.

globenewswire.com•2026-07-15

$HAREHOLDER ALERT: The M&A Class Action Firm Encourages $hareholders to Act Before the Vote—Cross Country Healthcare, Inc. (NASDAQ: CCRN)

NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Cross Country Healthcare, Inc. (NASDAQ:  CCRN ) related to its sale to KL Criss Cross Intermediate, LLC. Under the terms of the proposed transaction Cross Country shareholders are expected to receive $13.25 per share in cash. Is it a fair deal?

globenewswire.com•2026-07-15

CCRN Alert: Monsey Firm of Wohl & Fruchter Renews Investigation of the Proposed Sale of Cross Country Healthcare to Knox Lane

MONSEY, N.Y., July 15, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP has renewed its investigation into the fairness of the proposed sale of Cross Country Healthcare (Nasdaq: CCRN) (“CCRN”) for $13.25 per share in cash to Knox Lane, a private equity firm.

globenewswire.com•2026-05-27

CCRN Investors Have Opportunity to Join Cross Country Healthcare, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, May 27, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cross Country Healthcare, Inc. (“Cross Country” or “the Company”) (NASDAQ: CCRN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

gurufocus.com•2026-05-21

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--CCRN, EEX, BLD, and QXO

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--CCRN, EEX, BLD, and QXO PR Newswire

globenewswire.com•2026-05-20

CCRN Investors Have Opportunity to Join Cross Country Healthcare, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, May 20, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cross Country Healthcare, Inc. (“Cross Country” or “the Company”) (NASDAQ: CCRN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

businesswire.com•2026-05-14

Cross Country Expands AI-Powered Workforce Intelligence for Health Systems Through Exclusive OptimĂŠ Solution

BOCA RATON, Fla.--(BUSINESS WIRE)--Cross Country Healthcare, Inc. (Nasdaq: CCRN), a technology-driven healthcare workforce solutions company, today announced an exclusive 36-month partnership to bring the OptimĂŠ workforce strategy and planning solution into IntellifyÂŽ, Cross Country's workforce intelligence platform. OptimĂŠ adds advanced forecasting, analytics and workforce optimization capabilities to Intellify, helping health systems better align workforce supply with patient demand, improve.

globenewswire.com•2026-05-13

CCRN Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Cross Country Healthcare to Knox Lane

MONSEY, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Cross Country Healthcare (Nasdaq: CCRN) (“CCRN”) for $13.25 per share in cash to Knox Lane, a private equity firm.

globenewswire.com•2026-05-11

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cross Country Healthcare, Inc. (NASDAQ: CCRN)

NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.

globenewswire.com•2026-05-08

CCRN Investors Have Opportunity to Join Cross Country Healthcare, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, May 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cross Country Healthcare, Inc. (“Cross Country” or “the Company”) (NASDAQ: CCRN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

zacks.com•2026-05-07

Cross Country Healthcare (CCRN) Reports Q1 Loss, Beats Revenue Estimates

Cross Country Healthcare (CCRN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.06 per share a year ago.

zacks.com•2026-05-07

Here's What Key Metrics Tell Us About Cross Country (CCRN) Q1 Earnings

While the top- and bottom-line numbers for Cross Country (CCRN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

businesswire.com•2026-05-07

Cross Country Healthcare Announces First Quarter 2026 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--Cross Country Healthcare, Inc. (the Company) (Nasdaq: CCRN) today announced financial results for its first quarter ended March 31, 2026. Selected Financial Information:         Variance Variance       Q1 2026 vs Q1 2026 vs Dollars are in thousands, except per share amounts Q1 2026 Q1 2025 Q4 2025 Revenue $ 241,057     (18) %   2 % Gross profit margin*   19.7 %   (30) bps   (60) bps Net loss attributable to common stockholders $ (4,266)     (771) %   95 % Dilu.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"Headline (2026-03-31, Q1): Revenue was $0 (reported), and Net Income was -$4.27M with EPS of -$0.14. On a year-ago basis (2025-03-31), Net Income loss widened from -$0.49M to -$4.27M (worse by about 769%). QoQ (vs. 2025-12-31), the loss improved: Net Income improved from -$82.93M in Q4 to -$4.27M in Q1 (~-95% improvement). Across the four-quarter window, the company swung from profitable/near-break even results to deeper losses, with net margin remaining negative throughout. Profitability: Gross margin was not reported for Q1 (0 values), but operating income was -$4.16M versus +$9.35M in Q4 and -$0.98M in Q1’25—indicating operating pressure returned. Cash flow & balance sheet: Operating cash flow was +$4.77M and free cash flow was +$4.77M in Q1, a sequential improvement from +$18.24M in Q4. The balance sheet remains liquid with cash $105.6M and total assets of $451.1M. Equity was $312.8M. Net debt is favorable at about -$103.5M (net cash). Shareholder returns: With price at $9.86 and 1-year change of -30.90% (no dividend shown; buybacks in Q4 only), total shareholder return momentum is weak. Analyst consensus target is $10.61 versus $9.86, implying modest upside."

Revenue Growth

Neutral

Revenue for 2026-03-31 is reported as $0, so growth rates are not meaningful. Historically revenue declined from $293.4M (2025-03-31) to $236.8M (2025-12-31), and $0 in the latest quarter prevents a reliable trajectory assessment.

Profitability

Neutral

Net income deteriorated YoY (loss -$4.27M vs -$0.49M; ~-769%) and was still unprofitable. QoQ improved materially (loss -$4.27M vs -$82.93M, ~95% improvement), but operating income remained negative at -$4.16M versus +$9.35M in Q4.

Cash Flow Quality

Neutral

Q1 generated positive operating cash flow (+$4.77M) and free cash flow (+$4.77M), despite net losses. However, this is below Q4 operating cash (+$18.24M), suggesting cash generation is improving but not consistently strong.

Leverage & Balance Sheet

Positive

Strong resilience: cash $105.6M and total assets $451.1M. Equity increased to $312.8M (from $322.8M in Q4), while net debt remains negative (net cash about -$103.5M). Short-term liquidity (current ratio ~3.29) is healthy.

Shareholder Returns

Neutral

Price performance is weak: -30.90% over 1 year. No dividend is indicated, and buybacks were only evident in earlier quarters (e.g., Q4 repurchase outflow). Total shareholder return momentum is a headwind.

Analyst Sentiment & Valuation

Fair

Consensus price target is $10.61 vs current $9.86 (~+7.7% implied upside). Valuation appears mixed (no clear earnings base given ongoing losses), with sentiment likely cautious due to volatility in profitability.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Management sounded confident about execution and called out a credible end-2026 target: >$1B revenue run-rate and 4%–5% adjusted EBITDA margin. However, in the Q&A the margin story was less about improving gross margins and more about cost/operating leverage—explicitly citing offshoring more work to India and automation, while acknowledging the travel market remains hypercompetitive and the bill-pay spread likely stays tight. The analyst pressure centered on “what needs to happen” to reach the higher margin exit rate; management’s answer leaned on return on revenue-producer investments plus operating leverage rather than any meaningful gross margin rescue. On labor disruption, management downplayed risk: Q4 revenue did not include any significant strike/labor disruption revenue, while Q1 impact was only in the single millions, used as evidence that disruptions won’t derail core momentum. Market-wise, they cited stabilization with average bill rates around $90–$95.

AI IconGrowth Catalysts

  • Return to more normal contingent utilization cycle (travel/nurse/allied) as travelers on assignment stabilize and rise into Q2
  • Investments in revenue producers (recruiters, account managers, sales professionals) starting early 2026; “sequential progression” expected
  • Expansion of proprietary technology (Intellify) beyond core MSP/VMS into additional “whole house” markets in 2026
  • Higher-margin mix contribution from home-based, physician, and education staffing businesses lifting consolidated gross margin over time

Business Development

  • Renewed/expanded/won >$400 million in contract value predominantly with MSP clients (from prior quarter highlight)
  • Whole-house strategy: positioning Intellify/VMS and staffing solutions across locums and home-based (Q&A scope of expansion includes home-based, education, locums)

AI IconFinancial Highlights

  • Q4 revenue: $237M, down 5% sequentially and down 24% YoY
  • Full-year revenue: $1.05B, down 22% YoY
  • Q4 gross margin: 20.3%; down 10 bps sequentially; up 30 bps YoY
  • Full-year adjusted EBITDA: $27M (2.5% of revenue); Q4 adjusted EBITDA: $4M (1.7% of revenue)
  • Guidance Q1 2026 revenue: $235M–$240M; exit 2026: Q4 revenue >$250M
  • Guidance Q1 2026 adjusted EBITDA: $4M–$5M (~2% margin); expected payroll tax headwind of ~$2M in Q1
  • Guidance gross margin assumption for Q1: 19.5%–20.0%
  • Q1 adjusted EPS: loss of $0.04 to $0.06 (avg ~31.5M shares)
  • Impairment/one-time items: noncash impairment charges of $78M related to indefinite-lived assets/goodwill and abandonment of trade names; merger termination payment produced a $20M credit (acquisition/integration net credit $16M Q4, $3M FY)

AI IconCapital Funding

  • Cash balance (Q4 end): $109M; no outstanding debt
  • Q4 share repurchase: >800,000 shares (~2.5% of shares outstanding) for $6.8M
  • Additional repurchases in Q1 2026 to date: 486,000 shares (as of call date)
  • FY cash from operations: $48M; Q4 cash from operations: $18M
  • Credit facility: exploring renewal/rightsizing to lower carrying costs of unused facility

AI IconStrategy & Ops

  • Margin exit path relies more on operating leverage than large gross margin expansion (hypercompetitive travel bill-pay spread expected to persist)
  • Operational levers cited for reaching 4%–5% EBITDA by end of 2026: offshoring more work to India center of excellence and automation of activities
  • ERP middle-office functionality rollout and AI to improve recruiter productivity/speed to market (prepared remarks; reinforced as efficiency lever)
  • DSO in Q4: 58 days (in line with 60-day goal)

AI IconMarket Outlook

  • Exit 2026 targets reiterated: revenue run rate >$1B and adjusted EBITDA margin of 4%–5%
  • Q1 2026 travel momentum: projected travelers on assignment rising through Q1; exit Q1 up ~2% vs Q4 average
  • Average bill rates cited by management (market backdrop): ~$90–$95; no “typical bump up” in Allied Health winter, implying consistent QoQ improvement in Allied and Travel Nursing
  • Travel outlook in prepared remarks: flat to up slightly sequentially; travelers on assignment growth each month into Q2
  • Intellify expansion timeline: 2026; “coming to market later this year, hopefully sooner”

AI IconRisks & Headwinds

  • Travel bill-pay spread compression and continued hypercompetitive travel market; management said they do not anticipate margin pressure easing for travel in the near term
  • Competitive pressures limit gross margin expansion; EBITDA improvement expected from operating leverage instead
  • Labor disruption/strike risk: management participated in two strike/labor disruption events; impact stated as “not material” in Q4 and “single millions” in Q1
  • International candidate pipeline risk: retrogression remains due to annual visa caps; backlog slowly clearing but is monitored
  • Payroll tax headwind: approximately $2M negative impact in Q1 2026 guidance

Sentiment: MIXED

Note: This summary was synthesized by AI from the CCRN Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for CCRN.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (CCRN)

© 2026 Stock Market Info — Cross Country Healthcare, Inc. (CCRN) Financial Profile